Noul Co Ltd

Noul Co Ltd's capital structure is characterized by a market price of 1221.0 KRW per share and a market cap of 62,626,705,383 KRW, with a price-to-book ratio of 2.44 and a price-to-tangible-book ratio of 2.44. The company's liquidity position is marked by a current ratio of 3.91, indicating strong short-term liquidity, but its operating cash flow of -20,531,114,400 KRW and free cash flow of -20,657,946,810 KRW suggest significant cash outflows. Profitability metrics show a return on equity of -0.777 and a return on assets of -0.5087, both well below the industry norms for Biotechnology & Medical Research, indicating poor returns on invested capital. The company's operating income of -20,089,801,870 KRW and net income of -19,954,848,720 KRW further underscore its unprofitable operations. The company's revenue is concentrated in a single business segment focused on diagnostic testing platforms, with no disclosed geographic diversification, suggesting a high degree of revenue concentration in its core operations. This lack of diversification increases exposure to sector-specific risks. Growth trajectory is not evident from the current financial data, as the company is reporting negative operating and net income. The outlook for the current fiscal year does not indicate a reversal of this trend, with no positive numeric deltas reported. Risk factors include a medium liquidity risk due to negative operating and free cash flows, and a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. Recent events include the latest financial filing (HA-latest), which discloses the company's current financial position and operational performance. No recent transcripts or additional filings are available to provide further insight into the company's strategic direction or operational changes.